Company Overview
Sanara MedTech Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings throughout the United States. The company's core product offering includes CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for specific clinical applications. As of the latest reported data, the company holds a market capitalization of $146.19M and employs 108 individuals to support its operational and distribution activities. With annual revenue of $103.12M, these valuation and scale metrics position Sanara MedTech as a mid-sized entity within the specialized medical technology space, indicating a focus on niche surgical markets rather than broad consumer or mass-market healthcare distribution.
Financial Health
The company reported revenue of $103.12M over the trailing twelve months, while recording a net income of -$387,683 and an EBITDA of $11.81M, revealing a significant divergence between top-line sales and bottom-line profitability. This gap between revenue and net income highlights a cost structure where non-operating expenses or interest costs, rather than core production costs, are likely driving the reported loss despite positive cash generation from operations. Despite the net loss, the firm maintains robust financial flexibility evidenced by a free cash flow of $8.54M, which suggests the business model is capable of generating sufficient liquidity to cover operational outlays and potentially fund growth initiatives without immediate reliance on external financing. Profitability analysis across three key margins shows a gross margin of 92.7%, indicating high efficiency in production or low cost of goods sold relative to sales; an operating margin of 10.5%, which reflects the efficiency of core business operations after internal expenses; and a profit margin of -36.4%, signaling that total expenses and interest obligations are currently exceeding total revenue. The balance sheet presents a leveraged profile with total debt of $48.19M against cash reserves of $16.58M, resulting in a debt-to-equity ratio of 812.73, which implies a high reliance on borrowed capital relative to shareholder equity. Liquidity analysis indicates a current ratio of 1.80, suggesting the company possesses sufficient current assets to cover its short-term liabilities, providing a necessary buffer against immediate financial obligations. Return metrics further clarify the financial picture, with a return on equity of -1.8% reflecting the dilutive impact of losses on shareholder value, while a return on assets of 7.1% indicates that the company's asset base is generating positive operating returns before financing costs.
Valuation Assessment
Valuation metrics for Sanara MedTech present a complex picture due to the company's current loss status, with a trailing P/E ratio listed as N/A and a forward P/E of -13.97. The negative forward P/E implies that analysts or market participants expect earnings to remain negative in the near future or that current losses are priced in without a clear immediate turnaround trajectory. A price-to-book ratio of 24.61 indicates that the market values the company at a significant premium over its net asset book value, which often occurs in technology or biotech sectors where intangible assets and future growth potential are not fully captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 1.42 and an EV/EBITDA of 15.36 provide perspective by normalizing for debt and revenue, suggesting the market is pricing the stock based on revenue multiple and enterprise value relative to operating cash flow rather than current earnings power. Price action analysis shows a 52-week high of $35.95 and a 52-week low of $16.05, with the current market price trading in the lower half of this range relative to the historical volatility observed over the past year. The stock exhibits a beta of 1.05, indicating that its price volatility is slightly higher than the broader market, meaning it tends to move with greater intensity than the overall index during periods of market fluctuation.
Growth & Income
The company demonstrates a revenue growth rate of 4.7% year-over-year, whereas earnings growth is N/A due to the negative net income position, implying that top-line expansion is currently outpacing any potential earnings recovery. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which means the firm retains all earnings—though currently losses—to reinvest directly into product development, market expansion, or operational scaling rather than distributing cash to shareholders. The absence of a dividend program combined with the 0.0% payout ratio confirms that Sanara MedTech prioritizes capital retention for internal growth initiatives over income distribution to investors. Overall, the growth and income profile is characterized by moderate top-line expansion funded by free cash flow, but with earnings metrics that remain in negative territory, focusing entirely on capital appreciation potential through future profitability rather than current income generation.